ArticleWorld journal of surgical oncology2025
RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) is a major hematologic malignancy with limited therapeutic progress in radiotherapy. Although radiotherapy is widely used for palliation, its molecular effects in MM remain poorly defined. This study identifies RPL29 as a novel radiotherapy-responsive gene in MM and evaluates its prognostic and therapeutic relevance.
methodsWe employed a multidisciplinary approach, including murine models, radiotherapy schedules, RNA sequencing (RNA-seq), quantitative polymerase chain reaction (qPCR), and bioinformatics. Clinical samples from MM patients (age, sex, and ethnicity recorded) were included for validation. Statistical analysis aimed to identify differentially expressed genes and assess their prognostic significance. Differential gene expression analysis was conducted on irradiated and control groups. Venn diagram analysis and protein-protein interaction (PPI) network construction were used to identify key regulatory genes.
resultsRNA-seq analysis revealed 424 upregulated and 33 downregulated genes in the 2 Gy local tumor radiotherapy group compared to control. The tumor suppressor gene ADIPOQ emerged as a hub gene in the PPI network. Among the validated downregulated genes was UPK3A, while RPL29, not RPL19, was found to be consistently downregulated in the 2 Gy group. This finding was replicated in MM cell lines and patient samples, supporting its role in disease progression. Distinct radiotherapy doses and delivery methods induced specific biological processes and KEGG pathways, underscoring dose-dependent transcriptional effects.
conclusionsRPL29 downregulation following 2 Gy radiotherapy correlates with improved prognosis in MM, highlighting its potential as a clinically relevant prognostic biomarker. These findings provide new insights into MM biology and establish a foundation for targeted therapeutic strategies involving RPL29 and related pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.